Seth Gleiman

PhD ChemE, med device strategist, polymer physicist, wildland firefighter, Ironman finisher, home gym aficionado

[Seth Gleiman @sethgleiman]

Recent results from @galvanizetx INCITE-ES clinical trial in early-stage #NSCLC indicate that our Aliya PEF system has the potential to stimulate an immune response as evidenced by tertiary lymphoid structure accumulation in PEF-treated patients vs control https://t.co/KgWZQnUIGx

[Galvanize Therapeutics, Inc. @galvanizetx]

Congratulations to Dr. Darryl Smith and Dr. Rayhan Hai at Michael E. DeBakey Veterans Affairs Medical Center for treating their first patient using the Aliya #PEF system! We are excited to partner with you!

#Aliya #PulsedElectricFields #iPeeps #InterventionalRadiology #InterventionalOncology

The Aliya System is 510(k) cleared in the United States for the surgical ablation of soft tissue. It is not currently commercially available in any other geography.

Galvanize Therapeutics does not promote the off-label use of its products and nothing herein is intended to promote an off-label use of the Aliya System. The Aliya System is a tool for the surgical ablation of soft tissues, and is not intended to treat, cure, prevent or mitigate any specific disease or condition.

[Galvanize Therapeutics, Inc. @galvanizetx]

Chronic Bronchitis affects around 10.3% of the world’s population aged 30–79 years, which is nearly 392 million people.* While there is no cure, it is treatable. To learn more about how we are developing therapies for COPD patients with Chronic Bronchitis, visit https://t.co/hwA6Fzm4yk.

#COPD #ChronicBronchitis #PEF #LungHealth #GalvanizeTX

The RheOx® system is an investigational device in the United States and is limited by Federal (or United States) law to investigational use. The RheOx system is CE mark certified and available commercially in the EU.

*Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022 May;10(5):447-458. doi: 10.1016/S2213-2600(21)00511-7. Epub 2022 Mar 10. PMID: 35279265; PMCID: PMC9050565.

[Galvanize Therapeutics, Inc. @galvanizetx]

A pre-clinical abstract featured at the American Society of Clinical Oncology #ASCO23 meeting showed that Aliya™ #PulsedElectricFields (PEF) delivered in combination with anti-PD1 therapy significantly reduced tumor growth and prolonged survival in mice with EMT6 triple-negative #BreastCancer #TNBC. Flow cytometry confirmed that T cells, B cells and Natural Killer cells were all increased in the PEF treated groups as compared to controls. This study demonstrates that PEF stimulates an innate and adaptive #ImmuneResponse that reduces tumor growth and prolongs survival of tumor-bearing mice versus immunotherapy alone.

To view the study, visit https://t.co/sPgPYrHirr. To learn more at about our Aliya System, visit https://t.co/TDNTHD3s9S!

#Aliya #PEF #InterventionalOncology #InterventionalRadiology #Immunotherapy #iPeeps

The Aliya System is 510(k) cleared in the United States for the surgical ablation of soft tissue. It is not currently commercially available in any other geography.

Galvanize Therapeutics does not promote the off-label use of its products and nothing herein is intended to promote an off-label use of the Aliya System. The Aliya System is a tool for the surgical ablation of soft tissues, and is not intended to treat, cure, prevent or mitigate any specific disease or condition.

[Stephen V Liu, MD @StephenVLiu]

Dr. @LealTiciana at #ASCO23 presents results from phase III LUNAR study of 2L SOC +/- Tumor Treating Fields (TTFields). TTFields involves wearing a vest (continuously) with transducers that deliver electric fields that disrupt mitosis and trigger immunogenic cell death. #LCSM

[Jonathan Spicer MD PhD @DoctorJSpicer]

Just like CM816, for those saying there is no OS effect, I ask you which curve do you prefer for your patients? Let’s just give it a bit of time, eh? @NEJM @ASCO @IASLC @AATSHQ @thoracic @ThoracicsCanada #ASCO23 https://t.co/T7nnHJAwo0

[Patrick Forde @FordePatrick]

Neoadjuvant chemo-immunotherapy AND adjuvant IO for lung cancer from Drs. ⁦@HwakeleeMD⁩ ⁦@DoctorJSpicer⁩ & colleagues! EFS HR 0.58, pCR rate 18.1%. Great study & confirms benefit of neoadj! Still not clear who needs adjuvant IO? #lcsm https://t.co/b9znAPDYW9

[Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD]

#ASCO23 @ASCO
KN671 - 1st IA: Periop ChemoIO + Adj IO

Dual endpts EFS/OS
N=797–>397 in P

✨~40% completed adj tx
✨1/3rd split across PDL1 levels
✨EFS HR=0.58, mEFS NR w P
✨OS HR=0.73

@OncoAlert @ASCOPost

[Galvanize Therapeutics, Inc. @galvanizetx]

Cancer research saves lives. This month we celebrate the many doctors and scientists worldwide that are dedicated to seeking innovative and effective new treatments to help cancer patients live longer, better lives. Thank you for your ongoing commitment to advancing science and improving patient outcomes.

#AACR #NCRM23 #CancerResearchSavesLives

[Jonathan Spicer MD PhD @DoctorJSpicer]

I can hear @AltorkiNasser's voice in the reply as if he's standing next to me. Hard to beat the master in terms of scientific rigour! The claim that sublobar resections fail to offer QoL benefit is not supported by data. The truth is that we do not yet know one way or another.

[H. Jack West, MD, FASCO @JackWestMD]

The answer here is NO. Having another option that provides no evidence of superiority but adds a year of treatment, w/its attendant toxicities & financial costs, is damning w/faint praise.
We don't need another option that offers no incremental benefit over what we already have.

[Stephen V Liu, MD @StephenVLiu]

Dr. @SheenaBhallaMD gives a thoughtful overview of overcoming resistance to immunotherapy in NSCLC at #TexasLung23. Many mechanisms and they will likely differ between primary and acquired resistance. Encouraging strategies in development but need biomarkers here.

[Dr Amol Akhade @SuyogCancer]

@PatelOncology @FordePatrick @JackWestMD @myESMO @StephenVLiu @n8pennell Sub group analysis was shown for PFS . Not for OS .

[Dr Amol Akhade @SuyogCancer]

Checkmate 816 . 3 year EFS .

[Dr Amol Akhade @SuyogCancer]

Data that everyone is waiting for . Checkmate 816 . 3 year OS . 78 %vs 64 % . HR 0.62 ( 0.36 - 1.05 ) lot of censoring at around 3rd year . Not yet mature . Not yet statistically significant. @FordePatrick @JackWestMD @myESMO #ELCC2023 @PatelOncology @StephenVLiu @n8pennell

[Jake (the 80s & 90s never ended in my world) Rudh @JakeRudh]

On this day in 1984, A brain, an athlete, a basket case, a princess and a criminal reported for detention at Shermer High School.

[Jarushka Naidoo @DrJNaidoo]

Neoadjuvant nivo+CT+/-ipi in early stage nsclc ⁦@MDAndersonNews⁩ ⁦@NatureMedicine⁩:

- 22pts in each arm; 86% had 3 planned cycles; 100% & 91% had surgery
- MPR 32.1% nivo+CT; 50% Ipi+Nivo+CT; pCR 18% both arms

⁦@OncoAlert⁩ #LCSM https://t.co/Si9bK1HlbT

[Interventional News @IN_publishing]

@BcellBruno on the tumour microenvironment, tertiary lymphoid structures & more from #immunology—plus how this is relevant to #IO and #IR @SIRspecialists #SIR23PHX

[Mohamed Abazeed, MD, PhD @theabzlab]

We were told by our immunotherapy radiation scientists that radiation is immune stimulatory. Many negative trials later, we are now told that radiation is in fact immune inhibitory. Not unique to be wrong, but to be diametrically wrong is impressive.

[International Lung Cancer Summit @LungSummit]

Plain language summary describing the goals & results of the CheckMate 816 study ⬇️

It's important such summaries exist as it allows medical information to be accessible for everyone.

#OpenAccess article by @FordePatrick, @nicogirardcurie & colleagues ➡️ https://t.co/p3xKic5zZ4

[Patrick Forde @FordePatrick]

As neoadjuvant is becoming flavor of the year(s) in lung cancer, see below a patient focused summary manuscript of the CheckMate 816 trial that led to approval of neoadjuvant chemo-immunotherapy for lung cancer. #LCSM